{"id":25,"date":"2013-10-05T14:24:22","date_gmt":"2013-10-05T14:24:22","guid":{"rendered":"http:\/\/www.amuep-agate.de\/cms\/aid\/"},"modified":"2026-11-17T15:05:01","modified_gmt":"2026-11-17T15:05:01","slug":"aid","status":"publish","type":"page","link":"https:\/\/www.amuep-agate.de\/cms\/pharmakoinformation\/aid-start\/aid\/","title":{"rendered":"AIDs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"has-ast-global-color-1-color has-text-color has-link-color wp-elements-1 wp-block-paragraph\" style=\"font-size:30px\"><strong>AGATE AID<\/strong> <strong>Stellungnahmen<\/strong><\/p>\n\n\n<ul class=\"wp-block-latest-posts__list wp-block-latest-posts is-layout-flow wp-block-latest-posts-is-layout-flow\"><li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/aid-gentests\/\">Gentests<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat.Matthias Sicklinger, Dr. rer. nat. Bianca Fay, Ap. Katharina Endres, Ap. Florian Ridders, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/guanfacin-vom-blutdrucksenker-zum-mittel-der-wahl-bei-adhs\/\">Guanfacin \u2013 Vom Blutdrucksenker zum Mittel der Wahl bei ADHS?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Julian Sch\u00f6llkopf, Apothekerin Sandra Unholzer, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/trevicta-ein-neues-intramuskulaeres-dreimonats-depot-praeparat\/\">Trevicta &#8211; ein neues intramuskul\u00e4res Dreimonats-Depot-Pr\u00e4parat<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Teresa Wagner, Apothekerin Bianca Fay, Apothekerin Sandra Unholzer, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/knochenbrueche-durch-opipramol\/\">Knochenbr\u00fcche durch Opipramol<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Nagia BenOmar, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/alleskoenner-vitamin-d\/\">Allesk\u00f6nner Vitamin D<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Apothekerin Sandra Unholzer, cand. rer. nat. Anika Rothmund, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/loxapin-ein-neues-antipsychotikum\/\">Loxapin \u2013 ein neues Antipsychotikum?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Ursula Walter, Dr. med. Katharina Wenzel\u2010Seifert, Prof. Dr. med. Dr. rer. nat Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/abilify-maintena-ein-neues-depotantipsychotikum\/\">Abilify\u00ae Maintena\u00ae &#8211; ein neues Depotantipsychotikum<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Beatrix Benz, Apothekerin Sandra Unholzer, Apothekerin Alexandra K\u00f6ppl, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/stellenwert-von-adspro-bei-adhs\/\">Stellenwert von ADSPro\u00ae bei ADHS<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Apothekerin Bianca Fay, Apothekerin Carina Rothammer, Apothekerin Sandra Unholzer, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/vortioxetin-ein-neues-antidepressivum\/\">Vortioxetin \u2013 ein neues Antidepressivum<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Sarah Cseh, Ap. Alexandra K\u00f6ppl, Dr. rer. nat. Benedikt Stegmann, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/lisdexamphetamindimesilat-bei-adhs\/\">Lisdexamphetamindimesilat bei ADHS<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Kristin Rottmann, Apotheker Benedikt Stegmann, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/tianeptin-ein-neues-antidepressivum\/\">Tianeptin \u2013 Ein neues Antidepressivum?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Angelika P\u00f6llath, Prof. Dr. med. Dr. rer. nat Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/wachstumsstoerungen-unter-therapie-mit-methylphenidat\/\">Wachstumsst\u00f6rungen unter Therapie mit Methylphenidat?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Apotheker Benedikt Stegmann, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, Dr. med. Marina Hiltl<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/comt-polymorphismus-und-gst-mangel\/\">COMT-Polymorphismus und GST-Mangel<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Monika Baier, Dr. med. Peter Lauer, Prof. Dr. med. Dr. rer nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/welches-diuretikum-bei-lithiumtherapie\/\">Welches Diuretikum bei Lithiumtherapie?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Julia Ortlieb, cand. rer. nat. Monika Baier, Dr. med. Josefine R\u00f6der-Aigner, Prof. Dr. med. Bruno Oerlinghausen, Prof. Dr. med. Dr. rer nat. Ekkehard Haen<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/1702\/\">Linezolid \u2013 ein Antibiotikum mit Bedeutung f\u00fcr die Psychiatrie?<\/a><div class=\"wp-block-latest-posts__post-excerpt\">Dr. med. Christine Goepfert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 9 (2004): Seite 68-69<\/div><\/li>\n<li><a class=\"wp-block-latest-posts__post-title\" href=\"https:\/\/www.amuep-agate.de\/cms\/aid\/stellungnahme-zu-rote-hand-briefen-anwendung-von-olanzapin-zyprexa-und-risperidon-risperdal-bei-aelteren-patienten\/\">Stellungnahme zu \u201eRote Hand Briefen\u201c \u2013 Anwendung von Olanzapin (Zyprexa\u00ae) und Risperidon (Risperdal\u00ae) bei \u00e4lteren Patienten<\/a><div class=\"wp-block-latest-posts__post-excerpt\">cand. rer. nat. Miriam Steur, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 7\/8 (2004): Seite 44<\/div><\/li>\n<\/ul>\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>2012<\/strong><\/span><strong>\n<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong> <em>Kardiovaskul\u00e4res Risiko bei ADHS-Behandlung<\/em> <\/strong><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Dr. med. Katharina Wenzel-Seifert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 10 (2012): Seite 49+50+52<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2012) &#8211; neurotrans_10_2012.pdf [244 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-3-AID-Kardiovaskulaeres-Risiko-bei-ADHS-neurotrans102012.pdf\">2012 3 AID Kardiovaskul\u00e4res Risiko bei ADHS<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-3-AID-Kardiovaskulaeres-Risiko-bei-ADHS-neurotrans102012.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong><em>Tics bei Kindern und Jugendlichen<\/em> <\/strong><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Franziska Menke, Dr. med. Katharina Wenzel-Seifert, Michael Babl, Arzt, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 7 (2012): Seite 43-45<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2012) &#8211; neurotrans_7_2012.pdf [238 KB]<\/span><br> <\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-2-AID-TICS-bei-Kindern-und-Jugendlichen-neurotrans072012.pdf\">2012 2 AID TICS bei Kindern und Jugendlichen<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-2-AID-TICS-bei-Kindern-und-Jugendlichen-neurotrans072012.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong><em>Rote Hand Briefe Citalopram Escitalopram?<\/em> <\/strong><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Dr. med. Katharina Wenzel-Seifert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">PPT 19. Jahrgang Heft 1 (2012): Seite 25-30<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Wissenschaftliche Verlagsgesellschaft Stuttgart (2012) &#8211; ppt-1-12_haen_rote-hand-briefe_1.pdf [207 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-1-AID-Rote-Hand-Briefe-Citalopram-PPT12012.pdf\">2012 1 AID Rote-Hand-Briefe Citalopram<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2012-1-AID-Rote-Hand-Briefe-Citalopram-PPT12012.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>2011<\/strong><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong><em>Risikoprofil bei SSRI am g\u00fcnstigsten?<\/em> <\/strong><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Roland Mendl, Dr. med. Annemarie Lenner, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 9 (2011): Seite 38+41<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2011) &#8211; neurotrans_9_2011.pdf [865 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-3-AID-Antidepressive-Therapie-bei-Glaukom-neurotrans92011.pdf\">2011 3 AID Antidepressive Therapie bei Glaukom<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-3-AID-Antidepressive-Therapie-bei-Glaukom-neurotrans92011.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong><em>Suizid durch Rizinsamen?<\/em> <\/strong><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Andrea Lamecker, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 6 (2011): Seite 44+45<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2011) &#8211; neurotrans_6_2011.pdf [264 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-2-AID-Suizid-durch-Rizinsamen-neurotrans62011.pdf\">2011 2 AID Suizid durch Rizinsamen<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-2-AID-Suizid-durch-Rizinsamen-neurotrans62011.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Asenapin &#8211; ein neues Antipsychotikum?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Katja Tischhauser, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 5 (2011): Seite 50+51<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2011) &#8211; neurotrans_5_2011.pdf [565 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-1-AID-Asenapin-ein-neues-Antipsychotikum-neurotrans52011.pdf\">2011 1 AID Asenapin &#8211; ein neues Antipsychotikum<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2011-1-AID-Asenapin-ein-neues-Antipsychotikum-neurotrans52011.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>2010<\/strong><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Haloperidol nicht mehr intraven\u00f6s?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Laura Hiesinger, Dr. med. Markus Wittmann, Wolfgang Schreiber, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 9 (2010): Seite 22+23<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2010) &#8211; neurotrans92010.pdf [114 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2010-2-AID-Haloperidol-nicht-mehr-intravenoes-neurotrans92010.pdf\">2010 2 AID Haloperidol nicht mehr intraven\u00f6s<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2010-2-AID-Haloperidol-nicht-mehr-intravenoes-neurotrans92010.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Fibromyalgie und GST-Defekt &#8211; \u00dcberlegungen zu therapeutischen Alternativen<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Jan Zaloga, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen]<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">NeuroTransmitter 3 (2010): Seite 34+37<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2010) &#8211; neurotrans32010.pdf [377 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2010-1-AID-Fibromyalgie-und-GST-Defekt-neurotrans32010.pdf\">2010 1 AID Fibromyalgie und GST-Defekt<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2010-1-AID-Fibromyalgie-und-GST-Defekt-neurotrans32010.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>2009<\/strong><\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Neues Depotneuroleptikum Zypadhera &#8211; Prek\u00e4res Postinjektionssyndrom<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Michael Hicks, Dr. med. Katharina Wenzel-Seifert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 10 (2009): Seite 46+48]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2009) &#8211; neurotrans102009.pdf [233 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2009-2-AID-Zypadhera-Prekaeres-Postinjektionssyndrom-neurotrans102009.pdf\">2009 2 AID Zypadhera: Prek\u00e4res Postinjektionssyndrom<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2009-2-AID-Zypadhera-Prekaeres-Postinjektionssyndrom-neurotrans102009.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Dunkle Materie der Pharmakovigilanz<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Dr. med. Markus Wittmann, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 7\/8 (2009): Seite 39+40]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2009) &#8211; neurotrans7\/82009.pdf [76 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2009-1-AID-Dunkle-Materie-der-Pharmakovigilanz-neurotrans782009.pdf\">2009 1 AID Dunkle Materie der Pharmakovigilanz<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2009-1-AID-Dunkle-Materie-der-Pharmakovigilanz-neurotrans782009.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Warum Citalopram nicht mit Pimozid kombinieren?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [A. Gail, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 11 (2008): Seite 55]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2008) &#8211; neurotrans112008.pdf [64 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-4-AID-Warum-Citalopram-nicht-mit-Pimozid-kombinieren-neurotrans112008.pdf\">2008 4 AID Warum Citalopram nicht mit Pimozid kombinieren?<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-4-AID-Warum-Citalopram-nicht-mit-Pimozid-kombinieren-neurotrans112008.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Kognitive Beeintr\u00e4chtigung unter Lamotrigin?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Nora Pfister<strong>, <\/strong>Apothekerin Christine Greiner, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 10 (2008): Seite 68+71]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2008) &#8211; neurotrans102008.pdf [142 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-3-AID-Kognitive-Beeintraechtigungen-unter-Lamotrigin-neurotrans102008.pdf\">2008 3 AID Kognitive Beeintr\u00e4chtigungen unter Lamotrigin?<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-3-AID-Kognitive-Beeintraechtigungen-unter-Lamotrigin-neurotrans102008.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\">&nbsp;<strong>Mit Omega-3-Fetts\u00e4uren gegen ADHS?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Apothekerin Christine Greiner, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 4 (2008): Seite 68+71]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2008) &#8211; neurotrans42008.pdf [116 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-2-AID-Mit-Omega-3-Fettsaeuren-gegen-ADHS-neurotrans42008.pdf\">2008 2 AID Mit Omega-3-Fetts\u00e4uren gegen ADHS?<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-2-AID-Mit-Omega-3-Fettsaeuren-gegen-ADHS-neurotrans42008.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Triptane und Antidepressiva &#8211; eine Risikoabsch\u00e4tzung?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Apothekerin Astrid Hader, Dr. Thomas Stammschulte, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 3 (2008): Seite 66+68]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2008) &#8211; neurotrans32008.pdf [99 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-1-AID-Triptane-und-Antidepressiva-Eine-Riskoabschaetzung-neurotrans32008.pdf\">2008 1 AID Triptane und Antidepressiva &#8211; Eine Risikoabsch\u00e4tzung<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2008-1-AID-Triptane-und-Antidepressiva-Eine-Riskoabschaetzung-neurotrans32008.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Appell an Vernunft und Verantwortung bei Clozapin-Verordnung!<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 2 (2006): Seite 78]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2006) &#8211; neurotrans22006.pdf [77 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-1-AID-Apell-an-Vernunft-und-Verantwortung-bei-der-Clozapin-Verordnung-neurotrans22006.pdf\">2006 1 AID Apell an Vernunft und Verantwortung bei Clozapin Verordnung<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-1-AID-Apell-an-Vernunft-und-Verantwortung-bei-der-Clozapin-Verordnung-neurotrans22006.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Wie sicher sind Arzneimittel?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 6 (2006): Seite 73]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2006) &#8211; neurotrans62006.pdf [105 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-2-AID-Wie-sicher-sind-Arzneimittel-neurotrans62006.pdf\">2006 2 AID Wie sicher sind Medikamente<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-2-AID-Wie-sicher-sind-Arzneimittel-neurotrans62006.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>SSRI: Riskant bei Brustkrebs?<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [cand. rer. nat. Stefanie Heinz, PD Dr. med. Franz Worek, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 11 (2006): Seite 69]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2006) &#8211; neurotrans112006.pdf [102 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-3-AID-SSRI-Riskant-bei-Brustkrebs-neurotrans112006.pdf\">2006 3 AID SSRI Riskant bei Brustkrebs?<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2006-3-AID-SSRI-Riskant-bei-Brustkrebs-neurotrans112006.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Depression bei Isotretinoin-Therapie<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Dr. med. Franz Worek, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 1 (2005): Seite 65]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2005) &#8211; neurotrans12005.pdf [60 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2005-2-AID-Depression-bei-Isotretinoin-Therapie-neurotrans-122005.pdf\">2005 2 AID Depression bei Isotretinoin Therapie<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2005-2-AID-Depression-bei-Isotretinoin-Therapie-neurotrans-122005.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <strong>Vorsicht mit Neuroleptika bei \u00e4lteren Patienten!<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, Dr. med. David Fischer-Barnicol, NeuroTransmitter 5 (2005): Seite 66]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2005) &#8211; neurotrans52005.pdf [73 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2005-1-AID-Vorsicht-mit-Neuroleptika-bei-aelteren-Patienten-neurotrans-052005.pdf\">2005 1 AID Vorsicht mit Neuroleptika bei \u00e4lteren Menschen<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2005-1-AID-Vorsicht-mit-Neuroleptika-bei-aelteren-Patienten-neurotrans-052005.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Psychose unter Voriconazol<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Dr. med. Christine Goepfert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, NeuroTransmitter 10 (2004): Seite 69-70]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2004) &#8211; neurotrans1022004.pdf [121 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2004-4-AID-Voriconazol-neurotrans102.pdf\">2004 4 AID Voriconazol<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2004-4-AID-Voriconazol-neurotrans102.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> <em><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"><strong>Off-label-use bei Parkinson-Psychose<\/strong><\/span><\/em><\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> [Prof. Dr. med. Dr. rer. nat. Ekkehard Haen, Dr. med. Birgit M\u00f6\u00dfner-Haug, NeuroTransmitter 10 (2004): Seite 68]<\/span><br><span style=\"font-size: 12pt; font-family: arial,helvetica,sans-serif;\"> Copyright: \u00a9 Urban &amp; Vogel (2004) &#8211; neurotrans1012004.pdf [75 KB]<\/span><\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2004-3-AID-off-label-use-Parkinson-Psychose-neurotrans101.pdf\">2004 3 AID &#8222;off-label use&#8220; bei Parkinson Psychose<\/a><a href=\"https:\/\/www.amuep-agate.de\/cms\/wp-content\/uploads\/2015\/11\/2004-3-AID-off-label-use-Parkinson-Psychose-neurotrans101.pdf\" class=\"wp-block-file__button wp-element-button\" download>Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AGATE AID Stellungnahmen &nbsp; 2012 Kardiovaskul\u00e4res Risiko bei ADHS-Behandlung [Dr. med. Katharina Wenzel-Seifert, Prof. Dr. med. Dr. rer. nat. Ekkehard Haen] NeuroTransmitter 10 (2012): Seite 49+50+52 Copyright: \u00a9 Urban &amp; Vogel (2012) &#8211; neurotrans_10_2012.pdf [244 KB] Tics bei Kindern und Jugendlichen [cand. rer. nat. Franziska Menke, Dr. med. Katharina Wenzel-Seifert, Michael Babl, Arzt, Prof. Dr. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":73,"menu_order":87,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_mc_calendar":[],"footnotes":""},"class_list":["post-25","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/pages\/25","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/comments?post=25"}],"version-history":[{"count":14,"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/pages\/25\/revisions"}],"predecessor-version":[{"id":1788,"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/pages\/25\/revisions\/1788"}],"up":[{"embeddable":true,"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/pages\/73"}],"wp:attachment":[{"href":"https:\/\/www.amuep-agate.de\/cms\/wp-json\/wp\/v2\/media?parent=25"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}